Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Characterizing the development of MDS in patients with CLL in the era of targeted therapies

Adam Kittai, MD, Ohio State University, Columbus, OH, comments on the importance of better understanding how patients with chronic lymphocytic leukemia (CLL) may develop secondary myelodysplastic syndromes (MDS) in the era of novel therapies including Bcl-2 and BTK inhibitors, highlighting the impact of high-risk mutations and briefly discussing the management of these patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Abbvie: Consultancy; Astrazeneca: Consultancy, Research Funding; Beigene: Consultancy; Janssen: Consultancy.